1 16

Cited 0 times in

Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study

Authors
Wee, CW; Kim, IH; Park, CK; Kim, JW; Dho, YS; Ohka, F; Aoki, K; Motomura, K; Natsume, A; Kim, N; Suh, CO; Chang, JH; Kim, SH; Cho, WK; Lim, DH; Nam, DH; Choi, JW; Kim, IA; Kim, CY; Oh, YT; Cho, O; Chung, WK; Kim, SH; Kim, E
Citation
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 129(2):347-351, 2018
Journal Title
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN
0167-81401879-0887
Abstract
BACKGROUND AND PURPOSE: A novel molecular recursive partitioning analysis classification has recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 mutation (IDH1mut) status for glioblastoma (GBM-molRPA) patients treated with temozolomide-based chemoradiation. The current study was initiated to validate the model in a multi-institutional study.
MATERIALS AND METHODS: Four-hundred seventy-one newly diagnosed GBM patients (validation cohort) were allocated to classes I-III of the previously reported GBM-molRPA model. Of the patients, 15.7%, 56.1%, and 28.2% patients were GBM-molRPA class I, II, and III, respectively. MGMTmeth and IDH1mut were observed in 32.3 and 8.8% of patients, respectively. In the training plus validation cohort of 692 patients, 16.2%, 60.8%, and 23.0% patients were class I, II, and III, respectively.
RESULTS: The median follow-up for survivors and the median survival (MS) of patients was 23.3 and 18.4months, respectively. The MS for GBM-molRPA class I, II, and III was 49.7 (95% CI, 22.8-76.6), 19.2 (95% CI, 16.2-22.1), and 13.8months (95% CI, 11.8-15.4) (P<.001 for all comparisons) in the validation cohort. In the training plus validation cohort, the MS was 58.5 (95% CI, 40.7-76.3), 21. (95% CI, 18.6-23.3), and 14.3months (95% CI, 12.5-16.1) (P<.001 for all comparisons) for class I, II, and III, respectively.
CONCLUSION: The GBM-molRPA is a valid model. This GBM-molRPA classification can be useful in clinics and guiding patient stratification in future clinical trials.
Keywords
GlioblastomaIDH1MGMTRecursive partitioning analysisValidation
DOI
10.1016/j.radonc.2018.09.001
PMID
30236994
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
AJOU Authors
오, 영택조, 오연
Files in This Item:
Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse